Federal Circuit Affirms: Biologics For Neutropenia Treatment Do Not Infringe
WASHINGTON, D.C. — A Florida federal judge did not err in rejecting allegations by Amgen Inc. and Amgen Manufacturing Limited (Amgen, collectively) that proposed biosimilar versions of two Amgen pegfilgrastim and...To view the full article, register now.
Already a subscriber? Click here to view full article